Provided by Tiger Trade Technology Pte. Ltd.

Pharvaris N.V.

38.86
+0.84002.21%
Post-market: 39.250.3900+1.00%19:36 EDT
Volume:998.00K
Turnover:39.28M
Market Cap:2.71B
PE:-12.98
High:40.46
Open:38.16
Low:38.10
Close:38.02
52wk High:43.25
52wk Low:20.65
Shares:69.86M
Float Shares:43.70M
Volume Ratio:0.45
T/O Rate:2.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.9943
EPS(LYR):-3.4871
ROE:-70.46%
ROA:-42.32%
PB:7.82
PE(LYR):-11.14

Loading ...

Pharvaris Price Target Maintained with a $42.00/Share by Wedbush

Dow Jones
·
Sep 08

Pharvaris Unveils CHAPTER-3 Phase 3 Topline Data and HAE Pipeline Milestones

TIPRANKS
·
Sep 08

Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Tuesday Amid Rising Oil Prices

MT Newswires Live
·
Sep 08

Pharvaris Gains After Genetic Disorder Drug Meets Late-Stage Trial Goal

Reuters
·
Sep 08

Shares of Pharvaris up 26.5% Premarket After Co's Genetic Disorder Drug Meets Main Goal in Late-Stage Trial

THOMSON REUTERS
·
Sep 08

Pharvaris Posts Strong Phase 3 HAE Prophylaxis Data for Oral Deucrictibant XR

TIPRANKS
·
Sep 08

Pharvaris announces positive topline data from deucrictibant in HAE attacks

TIPRANKS
·
Sep 08

Pharvaris Says Phase 3 Chapter-3 Trial Shows 83% Cut in HAE Attack Rate for Deucrictibant XR vs Placebo

Reuters
·
Sep 08

Pharvaris N.v. - Plans to Submit Nda to FDA for Deucrictibant Xr in First Half 2027

THOMSON REUTERS
·
Sep 08

Pharvaris N.v. - All Secondary Efficacy Endpoints Met with Statistical Significance in Chapter-3 Study

THOMSON REUTERS
·
Sep 08

Pharvaris Announces Positive Topline Data from Chapter-3 Pivotal Study of Deucrictibant Xr for Prophylaxis of Hae Attacks

THOMSON REUTERS
·
Sep 08

Pharvaris N.v. - Topline Data from Creaate Phase 3 Study Expected First Quarter 2027

THOMSON REUTERS
·
Sep 08

Pharvaris N.v. - Chapter-3 Study Met Primary Endpoint with 83% Attack Rate Reduction Versus Placebo

THOMSON REUTERS
·
Sep 08

Pharvaris N.v. - 87% Attack Rate Reduction Versus Placebo in Hae Type 1 or Type 2 Patients

THOMSON REUTERS
·
Sep 08

Pharvaris N.v. - Deucrictibant Xr Demonstrated Well-Tolerated Safety Profile in Chapter-3 Study

THOMSON REUTERS
·
Sep 08

Pharvaris Reports Phase 2 Chapter-1 Extension Data Showing Long-Term Safety, Attack-Rate Drop for Deucrictibant in HAE

Reuters
·
Sep 03

Pharvaris (PHVS) Gets a Buy from Morgan Stanley

TIPRANKS
·
Aug 31

Analysts Offer Insights on Healthcare Companies: Pharvaris (PHVS), Caribou Biosciences (CRBU) and Aveanna Healthcare Holdings (AVAH)

TIPRANKS
·
Aug 14

Pharvaris Could See Significant Upside on Positive Phase 3 Data, RBC Says

MT Newswires Live
·
Aug 14

Pharvaris N.v. : Bofa Global Research Raises Price Objective to $38 from $35

THOMSON REUTERS
·
Aug 13